AIDS Alert Archives – November 1, 2006
November 1, 2006
View Issues
-
Routine HIV screening could be key to finding the unknown infected
To Americans who donate blood or buy life insurance, the routine HIV test long has been a part of the process. For pregnant women, it's increasingly a part of their prenatal care. But to the millions of Americans who visit an emergency room or sexually-transmitted disease (STD) clinic each year, HIV screening has been offered as a slightly inconvenient add-on health feature. -
Michigan devises plan for routine testing in ERs
When Michigan public health officials reviewed HIV counseling and testing programs, they concluded they had penetrated as deeply as possible into the communities they served, with about 400 test sites statewide, and yet it seemed the program's effectiveness had reached a plateau. -
Investigators find genetics help explain HIV dementia
A definite marker that explains HIV dementia remains elusive, but investigators recently found a possible explanation within viral genetic differences. -
Adherence Strategies: Hospital program reduces ART errors by 50 percent
Even with computerized patient records, a hospital located in an ethnically diverse area of the country had medication errors among HIV patients. -
ADAP problems continue as waiting lists top 300
Budgetary problems in funding antiretroviral drugs, which have been growing over the past five years, have led to a situation in which perhaps tens of thousands of HIV/AIDS patients know their status but are not in treatment because they have given up on the system, experts say. -
Palliative care model lost in today's HIV/AIDS care
HIV treatment and care have been so successful in resource wealthy nations that one unintended byproduct has been that clinicians are less focused on patients' comfort and quality of life than they were when so many of their patients were dying. -
FDA approves ddI generic version
The FDA, on Oct. 5, 2006, granted tentative approval for didanosine (ddI) for Oral Solution (Pediatric Powder), 10 mg/mL, manufactured by Aurobindo Pharma Limited Inc., of Hyderabad, India. -
AIDS Alert International: HIV Prophylaxis Still has no Clear Cut Answer
Researchers continue to study the use of a chemoprophylaxis for the prevention of HIV infection among at-risk groups around the globe, but the results public health officials hope to find remain elusive. -
AIDS Alert International: CDC's global AIDS outlook gives preview of WHO report
Africa remains the hardest hit of the worldwide HIV/AIDS pandemic, accounting for 64 percent of all people living with HIV/AIDS, while only having 10 percent of the world's population, an expert says.